<DOC>
	<DOC>NCT00988884</DOC>
	<brief_summary>This study will evaluate the tolerability and immunogenicity of administration of the first dose of V503 at the same time as Menactra™ and Adacel™ versus administration of V503 one month prior to administration of Menactra™ and Adacel™.</brief_summary>
	<brief_title>A Study of V503 Given Concomitantly With Menactra™ and Adacel™ in 11 to 15 Year Olds (V503-005)</brief_title>
	<detailed_description />
	<mesh_term>Papillomavirus Infections</mesh_term>
	<criteria>Subject is in good health Subject's parent/legal guardian can read, understand, and complete the vaccine report card Subject is not sexually active and does not plan on becoming sexually active during the study Subject has received a documented full primary immunization series against diphtheria, tetanus, and pertussis (not in the last 5 years) Subject has a known allergy to any vaccine component of V503, Menactra™, or Adacel™ Subject has a condition that is a contraindication to vaccination with Menactra™ or Adacel™ Subject has any coagulation disorder Female subject is pregnant Subject is immunocompromised or immunodeficient Subject has had a splenectomy Subject has received immunosuppressive therapies in the prior year Subject has received any immune globulin product or bloodderived product in the last 3 months Subject has received inactivated vaccines within 14 days or live vaccines within 21 days of the first study vaccination Subject has received a marketed HPV vaccine or has participation in an HPV vaccine trial Subject has received a meningococcal vaccine Subject has a fever &gt;= 100F within 24 hours of vaccination Subject has a history of HPV</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>